News Mundipharma to market Herceptin biosimilar in key EU markets Mundipharma's third biosimilar tie-up with Celltrion
News Its Herceptin biosimilar nearing launch, Celltrion begins wo... South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda.
News Pfizer's rituximab biosimilar gets late-stage trial boost Phase 3 success sets up showdown with Roche, Sandoz, and Celltrion
News Roche's Herceptin facing further biosimilar threats in US Breast cancer blockbuster facing potential trio of US competitors.
News Celltrion's rituximab biosimilar could have four names in EU Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
